Vivos Therapeutics (VVOS) Net Income towards Common Stockholders (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$7.7 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 98.81% year-over-year to -$7.7 million in Q1 2026; TTM through Mar 2026 was -$25.0 million, a 121.77% decrease from a year earlier, with the FY2025 full-year figure at -$21.2 million, down 89.66% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$7.7 million, down from -$7.0 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for VVOS reached as high as $9.4 million in Q4 2023 and fell as low as -$7.7 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$3.8 million across 5 years, with a median of -$5.0 million in 2025.
• Across the five-year window, Net Income towards Common Stockholders soared 253.83% in 2023 and plunged 159.74% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$6.1 million in 2022, then surged by 253.83% to $9.4 million in 2023, then plunged by 130.8% to -$2.9 million in 2024, then slumped by 141.04% to -$7.0 million in 2025, then retreated by 10.47% to -$7.7 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$7.7 million in Q1 2026, -$7.0 million in Q4 2025, and -$5.4 million in Q3 2025.